firstwordpharmaMarch 26, 2019
Tag: Hepatitis B virus , daratumumab , reactivation
Healthcare professionals including haematologists, oncologists, oncology nurses, oncology pharmacists, and other healthcare professionals providing care to cancer patients, including those who work in hospitals, cancer centres, oncology clinics and hospital pharmacies
Cases of HBV reactivation, some with a fatal outcome, have been reported in patients treated with DARZALEX. As of December 14, 2018, there were 15 cases of HBV reactivation in patients treated with DARZALEX. No Canadian cases of HBV reactivation related to DARZALEX treatment have been reported.
DARZALEX (daratumumab), concentrate for infusion solution, 20 mg / mL, in 5mL and 20mL single use vials
DARZALEX has received market authorization in Canada for use in the following clinical settings:
A recent cumulative review of clinical trial and post-marketing data identified 15 cases of HBV reactivation in patients treated with DARZALEX. Ten of the 15 cases were reported as serious. Of the 10 serious cases, 2 cases had a fatal outcome. No Canadian cases of HBV reactivation related to DARZALEX treatment have been reported at the time of the cumulative analysis. As of November 15, 2018, DARZALEX has been received by approximately 4,407 patients in clinical trial settings, and an estimated world-wide post-marketing exposure of 34,316 person-years. The estimated patient exposure in Canada is 390 person-years. The overall frequency of HBV reactivation in DARZALEX clinical trials, including serious and non-serious reports, is uncommon (0.2%). The majority of clinical trial cases were considered non-serious, although fatal HBV reactivation cases have been reported in clinical trials and in the post-market setting.
DARZALEX is used in adults 18 years or older to treat a type of cancer called multiple myeloma. This is a cancer of plasma cells which are found in bone marrow.
DARZALEX could cause the hepatitis B virus to become active again (hepatitis B virus reactivation) in patients with previously stable or undetectable levels. Patients should tell their doctor if they have ever had or might now have a hepatitis B infection.
Patients should contact their healthcare professional for more details on this new safety information.
Patients should immediately tell their healthcare professional if they get worsening tiredness or yellowing of the skin or white part of the eyes, as these may be symptoms of hepatitis B virus reactivation.
Register as Visitor to CPhI China 2019!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: